Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Immune Checkpoint Inhibition: Therapeutic Implications in Epithelial Ovarian Cancer

Author(s): Teresa C. Longoria and Ramez N. Eskander

Volume 10 , Issue 2 , 2015

Page: [133 - 144] Pages: 12

DOI: 10.2174/1574892810666150504121000

Price: $65

Abstract

Ovarian cancer accounts for more deaths than any other gynecologic malignancy. According to the Ovarian Cancer National Alliance, overall mortality rates due to ovarian cancer have not significantly improved in 40 years, a statistic that highlights the need for innovative treatment strategies. Immune checkpoint inhibitors are part of an emerging immunotherapeutic model that seeks to “inhibit the inhibitors” of adequate cancer immunosurveillance. Immune checkpoints encompass a variety of inhibitory pathways that downregulate an immune response, which allows them to assume an important physiologic role in maintaining homeostasis. While cancer cells are adept at utilizing these pathways to their advantage, basic scientists, translational researchers, and clinical trialists are making great strides in this area of investigation. This review article will focus on the development of anti-CTLA-4 and anti-PD1 monoclonal antibodies, their current role in the treatment of advanced stage EOC, and recently published patents that incorporate the use of immune checkpoint inhibition in the treatment of cancer.

Keywords: Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), immune checkpoint, immunoediting, ipilimumab, nivolumab, ovarian cancer, pembrolizumab, programmed cell death protein 1 (PD-1).


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy